Persist AI key facts
as of Oct 2026- Developer of AI-enabled cloud formulations intended to accelerate drug development and improve patient lives.
- Persist AI is valued at approximately $42.0M as of Oct 2026 (last reported valuation).
- It has raised $20.7M; the latest was Early Stage VC ($12.0M) in May 2025.
- Notable investors include Y Combinator, Pioneer Fund, Global Brain, SignalFire, Asymmetry Ventures — 18 tracked in total.
- Status: Privately Held (backing).
Persist AI's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch Persist AI: the Monday email on marks, rounds and moves
Persist AI funding rounds
No funding rounds for Persist AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Persist AI
18+Membership and data by Private Market View
Persist AI valuation
Persist AI's last reported valuation was $42 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Persist AI investors
18 investors are on record for Persist AI, including Y Combinator, Pioneer Fund, Global Brain and SignalFire. By type, the record holds 9 venture capital firms.
About Persist AI
Developer of AI-enabled cloud formulations intended to accelerate drug development and improve patient lives. The company focuses on using artificial intelligence-driven automation technologies such as automated drug release testing, high-throughput formulation screening, and method transfer and manufacturing scale-up, enabling drug manufacturers to speed up drug formulation.
- Sector
- Healthcare
- HQ
- West Sacramento, CA, United States
- Founded
- 2022
- Employees
- 10
- Website
- persist-ai.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.